(Q36804951)

English

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

scientific article published on 3 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial (English)

1 reference

Europe PubMed Central

16 August 2017

randomized controlled trial

1 reference

based on heuristic

inferred from title

zoledronic acid

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

object named as

Kim Cocks

4

0 references

Gareth J Morgan

object named as

Gareth J Morgan

1

0 references

author name string

Faith E Davies

2

1 reference

Europe PubMed Central

16 August 2017

Walter M Gregory

3

1 reference

Europe PubMed Central

16 August 2017

Sue E Bell

5

1 reference

Europe PubMed Central

16 August 2017

Alex J Szubert

6

1 reference

Europe PubMed Central

16 August 2017

Nuria Navarro-Coy

7

1 reference

Europe PubMed Central

16 August 2017

Mark T Drayson

8

1 reference

Europe PubMed Central

16 August 2017

Roger G Owen

9

1 reference

Europe PubMed Central

16 August 2017

Sylvia Feyler

10

1 reference

Europe PubMed Central

16 August 2017

A John Ashcroft

11

1 reference

Europe PubMed Central

16 August 2017

Fiona Ross

12

1 reference

Europe PubMed Central

16 August 2017

Jennifer Byrne

13

1 reference

Europe PubMed Central

16 August 2017

Huw Roddie

14

1 reference

Europe PubMed Central

16 August 2017

Claudius Rudin

15

1 reference

Europe PubMed Central

16 August 2017

Gordon Cook

16

1 reference

Europe PubMed Central

16 August 2017

Graham H Jackson

17

1 reference

Europe PubMed Central

16 August 2017

J Anthony Child

18

1 reference

Europe PubMed Central

16 August 2017

National Cancer Research Institute Haematological Oncology Clinical Study Group

19

1 reference

Europe PubMed Central

16 August 2017

language of work or name

0 references

publication date

3 December 2010

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

376

1 reference

Europe PubMed Central

16 August 2017

1989-1999

1 reference

Europe PubMed Central

16 August 2017

9757

1 reference

Europe PubMed Central

16 August 2017

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

How to treat a newly diagnosed young patient with multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Treatment of multiple myeloma: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

The safety of zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Bone complications in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Bisphosphonates: preclinical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

29 September 2017

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

5 September 2018

Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

5 September 2018

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

5 September 2018

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

5 September 2018

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

5 September 2018

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

5 September 2018

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3639680

5 September 2018

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962051-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962051-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962051-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)62051-X

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36804951&oldid=1522572442"